On Tuesday, Keros Therapeutics Inc (NASDAQ: KROS) was -4.80% drop from the session before settling in for the closing price of $68.15. A 52-week range for KROS has been $27.31 – $73.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -40.00% over the past five years. When this article was written, the company’s average yearly earnings per share was at -1.54%. With a float of $32.22 million, this company’s outstanding shares have now reached $40.51 million.
Let’s look at the performance matrix of the company that is accounted for 136 employees. In terms of profitability, gross margin is -27.5%, operating margin of -31341.63%, and the pretax margin is -27890.94%.
Keros Therapeutics Inc (KROS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Keros Therapeutics Inc stocks. The insider ownership of Keros Therapeutics Inc is 20.47%, while institutional ownership is 75.24%. The most recent insider transaction that took place on Aug 13 ’24, was worth 11,002,500. In this transaction Director of this company sold 250,000 shares at a rate of $44.01, taking the stock ownership to the 119,522 shares. Before that another transaction happened on Aug 13 ’24, when Company’s Director sold 250,000 for $44.01, making the entire transaction worth $11,002,500. This insider now owns 119,522 shares in total.
Keros Therapeutics Inc (KROS) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.34 earnings per share (EPS) during the time that was better than consensus figure (set at -1.37) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.80% during the next five years compared to -111.11% drop over the previous five years of trading.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
You can see what Keros Therapeutics Inc (KROS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 19.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4043.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.21, a number that is poised to hit -1.41 in the next quarter and is forecasted to reach -5.78 in one year’s time.
Technical Analysis of Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (NASDAQ: KROS) saw its 5-day average volume 0.5 million, a positive change from its year-to-date volume of 0.37 million. As of the previous 9 days, the stock’s Stochastic %D was 74.80%. Additionally, its Average True Range was 2.72.
During the past 100 days, Keros Therapeutics Inc’s (KROS) raw stochastic average was set at 81.66%, which indicates a significant increase from 57.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.68% in the past 14 days, which was lower than the 44.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $58.99, while its 200-day Moving Average is $55.36. Nevertheless, the first resistance level for the watch stands at $67.56 in the near term. At $70.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $71.82. If the price goes on to break the first support level at $63.29, it is likely to go to the next support level at $61.70. Assuming the price breaks the second support level, the third support level stands at $59.02.
Keros Therapeutics Inc (NASDAQ: KROS) Key Stats
There are 40,507K outstanding shares of the company, which has a market capitalization of 2.63 billion. As of now, sales total 150 K while income totals -152,990 K. Its latest quarter income was 390 K while its last quarter net income were -52,960 K.
